Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment

References

• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet354, 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med.340, 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med.130, 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The armada trial. Arthritis Rheum.48, 35–45 (2003).
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical and functional outcomes with adalimumab (a human anti-TNF monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum.50, 1400–1411 (2004).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Young A, Eberhardt K. The cost effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology42, 326–335 (2003).
   PubMed Web of Science ®Google Scholar
• Wong JB, Gurkipal S, Kavanaugh A. Estimating the cost- effectiveness of 54 weeks of Infliximab for rheumatoid arthritis. Am. J. Med.113, 400–408 (2002).
   PubMed Web of Science ®Google Scholar
• Barbieri M, Wong JB, Drummond MF. The cost–effectiveness of infliximab for treatment of severe rheumatoid arthritis in the United Kingdom. Pharmacoeconomics23(6), 607–618 (2005).
   Google Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology43, 62–72 (2004).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Singh A, Klareskog L. Cost–effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis.64, 1174–1179 (2005).
   PubMed Web of Science ®Google Scholar
• Bansback N, Brennan A, Ghatneker O. Cost–effectiveness of Adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann. Rheum. Dis.64, 995–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, NY, USA (2004).
   Google Scholar
• Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis.63, 4–10 (2004).
   PubMed Web of Science ®Google Scholar
• Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess.6(21) 1–110 (2002).
   PubMedGoogle Scholar
• Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess.8(11), iii, 1–91 (2004).
   Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost–effectiveness. Health Technol. Assess.10, 1–248 (2006).
   Web of Science ®Google Scholar
• Wailoo A, Brennan A, Bansback N, Nixon R, Wolfe F, Michaud K. Modeling the cost–effectiveness of etanercept, adalimumab and anakira compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare Program. Tech. Assess. Prog.1–74 (2006).
   Google Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics24, 1221–1232 (2006).
   PubMed Web of Science ®Google Scholar
• Hernández-Cruz B, Rubio-Terrés C, Ariza-Ariza R, Domínguez-Gil Hurle A, Navarro-Sarabia F. Evaluación económica de etanercept frente a infliximab-metotrexato en el tratamiento de la artritis reumatoide resistente a fármacos antirreumáticos modificadores de la enfermedad. Pharmacoeconomics Spanish Research Articles1(2), 73–85 (2004).
   Google Scholar
• Nuijten M, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost–cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics19(10), 1051–1064 (2001).
   PubMed Web of Science ®Google Scholar
• Blumenauer B, Judd M, Wells G et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev.3, CD003785 (2002).
   Google Scholar
• Geborek P, Crnkic M, Petersson IF, Saxne T, South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann. Rheum. Dis.61, 793–798 (2002).
   PubMed Web of Science ®Google Scholar
• St Clair W, van der Heijde D, Smolen J et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum.50(11), 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Genovese MC. Etanercept vs MTX in patients with early RA. Arthritis Rheum.46(8), 1443–1450 (2002).
   PubMed Web of Science ®Google Scholar
• Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol.36, 551–559 (1997).
   PubMedGoogle Scholar
• Caldwell DM, Ades AE, Higgins JPG. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br. Med. J.331, 897–900 (2005).
   PubMed Web of Science ®Google Scholar
• Ades AE, Sculpher M, Sutton A et al. Bayesian methods for evidence synthesis in cost–effectiveness analysis. Pharmacoeconomics24, 2–29 (2006).
   Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med.23, 3105–3124 (2004).
   PubMed Web of Science ®Google Scholar
• Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat. Med.26(6), 1237–1254 (2006).
   Google Scholar
• Briggs AH, O’Brien BJ. The death of cost–minimization analyisis? Health Econ.10(2), 179–184 (2001).
   PubMed Web of Science ®Google Scholar